Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of <i>Enterobacteriaceae</i> and Enterococci
Laurine Blanchard, Thomas P. Armstrong, Michael Kresken, Christopher L. Emery, Ying Yun, Véronique Sauvonnet, Gilles Zambardi
Abstract
Eravacycline (ERV) (brand name Xerava [Tetraphase]) is a new tetracycline-class antibacterial that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of complicated intra-abdominal infections (cIAIs).
Topics & Concepts
EtestBroth microdilutionEnterococcusEnterobacteriaceaeMicrobiologyBiologyMedicineVeterinary medicineEscherichia coliAntimicrobialAntibioticsMinimum inhibitory concentrationGeneBiochemistryAntibiotic Resistance in BacteriaBacterial Identification and Susceptibility TestingPharmaceutical and Antibiotic Environmental Impacts